Advance in Transdermal Drug Delivery System A review of Current status and Future Directions

Abstract

Transdermal Drug Delivery Systems (TDDS) represent a significant advancement in modern pharmaceutical technology, offering a non-invasive and patient-friendly alternative to conventional drug administration routes. By delivering drugs across the skin into systemic circulation, TDDS bypass hepatic first-pass metabolism, enhance bioavailability, reduce gastrointestinal side effects, and improve patient compliance. Traditionally limited to small, lipophilic, and low-dose drugs, transdermal delivery has expanded due to recent technological innovations. Current advancements focus on overcoming the barrier function of the stratum corneum using chemical penetration enhancers and physical techniques such as iontophoresis, sonophoresis, electroporation, and microneedle arrays. Nanotechnology-based carriers including liposomes, ethosomes, niosomes, solid lipid nanoparticles, and nanoemulsions have further improved drug permeation and stability. These developments enable the transdermal administration of macromolecules, peptides, and vaccines that were previously unsuitable for this route. Despite challenges such as limited drug loading capacity, potential skin irritation, and variability in permeability, ongoing research in smart polymers, biodegradable microneedles, and wearable patches shows promising future directions. TDDS continues to evolve as a controlled, targeted, and efficient drug delivery platform for chronic disease management and advanced therapeutics

Keywords

Transdermal Permeation Technologies; Iontophoretic Delivery; Electroporation Technique; Microneedle Arrays; Nano-vesicular Systems; Smart Wearable Patches; Personalized Transdermal Therapy; 3D-Printed Patches.

Introduction

1.1 Transdermal Drug Delivery System

Transdermal Drug Delivery Systems are specialized drug delivery platforms designed to transport therapeutically active agents through the skin directly into systemic circulation [1]. Unlike conventional oral or injectable routes, TDDS offers controlled and sustained release of drugs over extended periods [2]. The system typically involves a drug-containing matrix or reservoir attached to a backing layer, which maintains intimate contact with the skin, often enhanced with permeation enhancers to facilitate drug passage through the stratum corneum—the skin’s outermost barrier [1].

1.2 Advantages of TDDS:

• TDDS provides avoidance of first-pass metabolism, which increases bioavailability of drugs that undergo extensive hepatic metabolism.
• It enables controlled and sustained drug release, maintaining steady plasma concentrations, reducing dosing frequency, and improving patient compliance [2].
• TDDS results in reduced gastrointestinal side effects, as the drug bypasses the digestive tract.
• The ease of termination allows rapid discontinuation if adverse effects occur, unlike depot injections [3].
• These systems can deliver a wide variety of drugs, including hormones, analgesics, cardiovascular drugs, and more, making TDDS a versatile approach in therapeutics [4].

1.3 Historical Development and Rationale

The concept of delivering drugs through the skin dates back to ancient times when herbal ointments and poultices were applied topically for therapeutic purposes [5]. The modern development of TDDS began in the late 20th century, driven by the need to improve patient compliance and therapeutic outcomes. A landmark event was the FDA approval of the Scopolamine patch in 1979 for motion sickness, which marked the first commercially successful transdermal system [1]. This success paved the way for subsequent TDDS innovations, including nicotine patches, hormone replacement therapies, and pain management systems [4]. The rationale behind TDDS is to exploit the skin as a non-invasive portal for systemic drug delivery while overcoming limitations of oral and injectable routes [2]. The approach minimizes fluctuations in drug levels, enhances bioavailability, and reduces the frequency of dosing [3]. Advances in material science, polymer chemistry, and permeation enhancer technology have further improved the efficiency and versatility of transdermal systems [2].

1.4 Importance of TDDS in Modern Therapeutics

Improved Patient Compliance: The convenience of a patch applied once daily or weekly reduces the burden of multiple oral doses or injections, especially in chronic therapies.

Sustained and Controlled Delivery: Many drugs require stable plasma concentrations for efficacy, and TDDS can maintain such levels, minimizing peaks and troughs associated with oral dosing.

Non-invasive Administration: Avoiding needles reduces pain, risk of infections, and needle-phobia issues [3].

Expanded Therapeutic Options: Drugs with poor oral bioavailability or those that undergo extensive first-pass metabolism can be efficiently delivered transdermally.

Personalized Therapy Potential: Modern TDDS can be engineered for variable release profiles, making them suitable for personalized medicine applications.

Emerging Applications: With ongoing research, TDDS is being explored for vaccines, gene therapy, and delivery of large biomolecules like peptides and proteins [2].

2. Anatomy and Physiology of Skin

The skin is the largest organ of the human body, accounting for approximately 15–20% of total body weight and covering an area of 1.5–2 m² in adults [5]. It serves multiple functions, including protection against mechanical and chemical injury, prevention of water loss, thermoregulation, sensory perception, immunological defense, and vitamin D synthesis. Skin is composed of three primary layers: the epidermis, dermis, and hypodermis (subcutaneous tissue) [6]. The epidermis acts as the outermost protective barrier and is primarily composed of keratinocytes, along with melanocytes, Langerhans cells, and Merkel cells [7]. The dermis lies beneath the epidermis, consisting of connective tissue rich in collagen and elastin, and contains blood vessels, lymphatics, nerve endings, hair follicles, sebaceous glands, and sweat glands [6]. The hypodermis is mainly composed of adipose tissue and connective tissue, providing insulation, energy storage, and mechanical cushioning [7]. Appendages such as hair follicles, sebaceous glands, sweat glands, and nails play roles in protection, thermoregulation, and may serve as alternate pathways for absorption [8]. Physiologically, the skin maintains homeostasis, regulates body temperature, enables sensation, and acts as an immune organ [6].

2.1 Structure of Human Skin

The skin is composed of three primary layers:

Epidermis

1. The epidermis is the outermost layer, 50–150 µm thick depending on the body site.
2. It is primarily made of keratinocytes, arranged in stratified layers.
3. Specialized cells include:
   1. Melanocytes: produce melanin, protecting against UV radiation.
   2. Langerhans cells: immune cells that detect pathogens.
   3. Merkel cells: mechanoreceptors involved in touch sensation.
4. Layers of the epidermis (from inner to outer):
   1. Stratum basale: basal layer with proliferating keratinocytes.
   2. Stratum spinosum: provides structural support via desmosomes.
   3. Stratum granulosum: contains keratohyalin granules for keratin formation.
   4. Stratum lucidum: present only in thick skin (palms and soles).
   5. Stratum corneum: outermost layer of dead keratinized cells forming the primary barrier.

Dermis

1. The dermis lies beneath the epidermis and is 0.6–3 mm thick.
2. Composed mainly of connective tissue, including collagen and elastin fibers, providing strength and elasticity.
3. Contains blood vessels, lymphatics, nerve endings, hair follicles, sebaceous glands, and sweat glands.
4. Divided into:
5. Papillary dermis: superficial layer with loose connective tissue, capillaries, and sensory receptors.
6. Reticular dermis: deeper layer with dense connective tissue, housing larger blood vessels and sweat glands.

Hypodermis

• The hypodermis is the deepest skin layer, mainly composed of adipose tissue and connective tissue.
• Functions as energy storage, thermal insulation, and shock absorption.
• Connects the skin to underlying muscles and bones.

3. Limitations of Transdermal Drug Delivery

3.1 Therapeutic and Patient-Compliance Benefits

• Transdermal drug delivery (TDDS) provides a non-invasive route of administration, eliminating the pain, discomfort, and infection risk associated with injections [11].
• TDDS enhances patient compliance, as patches can be applied once daily or weekly, reducing the burden of frequent dosing [12].
• It allows for rapid discontinuation of drug therapy in case of adverse effects, unlike depot injections or sustained-release oral formulations [13].
• TDDS can improve quality of life for chronic patients by minimizing the need for hospital visits and invasive procedures.

3.2 Challenges and Limitations

• The stratum corneum acts as a significant barrier, limiting the transdermal absorption of hydrophilic or high-molecular-weight drugs [14].
• Only drugs with suitable physicochemical properties—low molecular weight, moderate lipophilicity, and potent activity—are ideal candidates for TDDS [14].
• Skin irritation or sensitization may occur due to the drug, adhesive matrix, or penetration enhancers [15].
• Variability in skin thickness, hydration, age, and site of application can lead to inconsistent drug absorption.
• TDDS may have limited dose capacity, making it unsuitable for drugs requiring high daily doses.
• The development of TDDS can be technically complex and expensive, involving specialized formulation and manufacturing processes [15].

4. Advanced Transdermal Drug Delivery Technologies (Current Status)

4.1 Chemical Enhancement Techniques

Penetration enhancers are chemical agents that temporarily reduce the barrier function of the stratum corneum, increasing drug permeability [16]. Common penetration enhancers include alcohols, fatty acids, surfactants, and terpenes, which disrupt lipid organization or increase drug solubility. Prodrugs are inactive derivatives of drugs chemically modified to improve lipophilicity or skin permeation; they are metabolized into active drugs after absorption [17]. Supersaturation strategies involve formulating drugs at concentrations above their solubility in the vehicle to create a thermodynamic driving force, enhancing skin permeation [18].

4.2 Physical Enhancement Techniques

Iontophoresis uses a low electrical current to drive charged molecules across the skin, increasing drug flux without disrupting skin integrity [19]. Sonophoresis (ultrasound) employs high-frequency ultrasound waves to temporarily disrupt the stratum corneum, enhancing drug penetration. Electroporation applies short electrical pulses to create transient micropores in the skin, facilitating the transport of macromolecules. Thermal ablation uses controlled heat to selectively remove portions of the stratum corneum, allowing drugs to penetrate more easily [20].

4.3 Microneedle-Based Drug Delivery Systems

Solid microneedles puncture the skin to create microchannels through which drugs can diffuse [21]. Coated microneedles have the drug coated on their surface, releasing it upon insertion into the skin. Dissolving microneedles are made of biodegradable polymers that encapsulate the drug, dissolving completely in the skin to release it. Hydrogel-forming microneedles swell upon insertion, creating a conduit for sustained drug delivery from an attached reservoir [22].

4.4 Vesicular and Nanocarrier-Based Systems

Liposomes are phospholipid bilayer vesicles that can encapsulate hydrophilic or lipophilic drugs, enhancing penetration and reducing irritation. Transfersomes are ultra-deformable liposomes capable of squeezing through narrow skin pores, improving transdermal delivery of large molecules [23]. Ethosomes are ethanol-containing vesicles that increase lipid fluidity in the stratum corneum, facilitating deeper drug penetration. Niosomes are non-ionic surfactant vesicles similar to liposomes, used to enhance stability and controlled release of drugs [24]. Nanoparticles and nanoemulsions provide high surface area and enhanced solubility, allowing improved permeation and targeted delivery through the skin [25].

5. Regulatory and Safety Considerations

5.1 Quality Control and Evaluation Parameters

Transdermal drug products must undergo rigorous quality control, including assessment of drug content uniformity, thickness, mechanical strength, adhesion, and in vitro drug release. Stability testing ensures the product maintains efficacy, safety, and physicochemical properties over its shelf life [26].

5.2 Skin Irritation and Sensitization

Safety evaluation includes testing for skin irritation, erythema, and sensitization, typically using in vitro models or human patch tests. Minimizing adverse effects is critical to ensure patient compliance and regulatory approval [27].

5.3 Regulatory Guidelines

Regulatory authorities like the FDA, EMA, and ICH provide guidelines for the development, testing, and approval of transdermal systems. Guidelines cover formulation, manufacturing, quality control, preclinical testing, and clinical evaluation, ensuring safety, efficacy, and reproducibility. Compliance with these regulations is mandatory for market authorization of transdermal drug products [28].

6. Challenges in Advanced TDDS Development

6.1 Skin Variability

Variations in skin thickness, hydration, lipid content, and barrier function between individuals and body sites can lead to inconsistent drug absorption. Age, gender, race, and disease states further influence permeation and therapeutic outcomes [29].

6.2 Manufacturing Scalability

Advanced TDDS, such as microneedles and nanocarriers, require precise fabrication techniques, which may be difficult to scale up for mass production. Maintaining batch-to-batch consistency is critical for regulatory approval and clinical reliability [30].

6.3 Stability and Storage Issues

Some transdermal systems, especially those containing biologics or nanocarriers, may have limited shelf-life due to degradation or aggregation. Temperature, humidity, and light exposure can affect drug content, adhesion, and mechanical properties of patches [31].

6.4 Patient Acceptance

Patient compliance can be affected by skin irritation, patch size, visibility, or discomfort during application. Acceptance is higher for non-invasive, painless, and convenient delivery systems, making design and usability critical factors [32].

7. Future Directions in Transdermal Drug Delivery

7.1 Personalized Transdermal Therapy

1. Personalized transdermal therapy represents a major trend in modern drug delivery, aiming to tailor patch formulations according to individual patient characteristics, such as age, gender, skin type, metabolic rate, and disease state.
2. By customizing drug release profiles and dosing regimens, personalized patches can maximize therapeutic efficacy while minimizing adverse effects.
3. Integration of patient-specific pharmacokinetic modeling with transdermal design allows for real-time optimization of therapy, especially in chronic conditions such as diabetes, cardiovascular disease, and hormone replacement therapy [33].

7.2 Integration with Nanotechnology and Artificial Intelligence (AI)

1. Nanotechnology offers opportunities to create advanced nanocarriers such as nanoparticles, nanocapsules, liposomes, transfersomes, and ethosomes, which can improve drug solubility, stability, and permeation through the skin.
2. These nanocarriers can also provide targeted and controlled delivery, reduce systemic side effects, and enable delivery of biomolecules such as peptides and proteins [34].
3. Artificial intelligence and machine learning techniques are increasingly being applied to predict skin permeability, optimize formulations, and design personalized TDDS.
4. AI can also facilitate real-time monitoring of patient adherence, enabling smart transdermal systems that adjust dosing or alert patients and clinicians to missed applications [35].

7.3 3D-Printed Transdermal Systems

1. 3D printing technology allows the fabrication of customized transdermal patches with complex geometries, controlled drug distribution, and multi-layer designs.
2. Through additive manufacturing, it is possible to combine multiple drugs in a single patch, enabling combination therapy with precise dosing for individual patients.
3. 3D printing also accelerates rapid prototyping and scaling of personalized patches, making it feasible to produce small-batch, patient-specific transdermal systems.
4. Such technologies open the door to integrating micro-reservoirs, microneedles, and nano-formulations within a single patch for enhanced delivery efficiency [36].

7.4 Long-Acting and Self-Regulated Patches

1. Long-acting transdermal patches are being developed to maintain steady therapeutic drug levels over extended periods, ranging from several days to months, reducing the need for frequent dosing.
2. Self-regulated or “smart” patches respond to physiological or biochemical signals such as glucose, pH, temperature, or other biomarkers to modulate drug release automatically.
3. Such closed-loop systems have significant potential in chronic disease management, including diabetes, hypertension, and pain therapy, by reducing the risk of under- or over-dosing.
4. Integration with wearable electronics and biosensors further enables remote monitoring and feedback-controlled drug delivery.
5. Future research is focusing on biodegradable and fully dissolvable patches, which reduce environmental impact and eliminate the need for patch removal [37].

CONCLUSION

Transdermal drug delivery systems (TDDS) have evolved significantly from conventional patches to highly advanced, multifunctional delivery platforms. Over the years, major advancements have been achieved through the use of chemical and physical enhancement techniques, microneedle-based systems, and vesicular as well as nanocarrier-based approaches. These innovations have helped overcome the primary barrier of the skin, expanded the range of deliverable drugs, and enabled controlled, sustained, and targeted drug release. Emerging technologies such as nanotechnology, artificial intelligence, and 3D printing are further transforming TDDS by enabling personalized therapy, smart self-regulated patches, and precise dose customization. Collectively, these developments highlight the growing potential of TDDS as a patient-friendly and efficient alternative to oral and injectable dosage forms.

From a clinical perspective, TDDS offers improved patient compliance, reduced dosing frequency, stable plasma drug concentrations, and minimized systemic side effects, making it particularly valuable for chronic disease management. Non-invasive administration and ease of therapy termination further enhance its clinical acceptability. From an industrial standpoint, transdermal systems represent a promising area for pharmaceutical innovation, product lifecycle extension, and market differentiation. However, challenges related to skin variability, large-scale manufacturing, stability, and regulatory compliance must be carefully addressed. Overall, with continued research and technological integration, TDDS is expected to play an increasingly important role in modern therapeutics and personalized medicine.

REFERENCES

1. N. Shrestha, D. N. Venkatesh, and J. Sharma, “Transdermal Drug Delivery System: An Overview,” Pharmatutor, 2011.  https://www.pharmatutor.org/articles/overview-of-transdermal-drug-delivery
2. V. D. Patil and S. B. Gosavi, “Comprehensive Review of Transdermal Drug Delivery Systems: Mechanisms, Materials, and Modern Innovations,” Asian J. Pharm. Res. Dev., 2025. https://www.ajprd.com/index.php/journal/article/view/1668
3. Transdermal Delivery – Overview,” ScienceDirect Topics, Elsevier. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/transdermal-delivery
4. “Transdermal Drug Delivery Systems,” Journal of Drug Discovery and Health Sciences, 2025.  https://jddhs.com/index.php/jddhs/article/download/75/91
5. L. F. Wolff, Textbook of Dermatology, 9th ed., New York: Springer, 2018.
6. J. L. Berman and M. M. Berner, “Anatomy and Physiology of Skin Relevant to Drug Delivery,” J. Clin. Pharmacol., vol. 58, no. 4, pp. 345–356, 2019.
7. A. R. Prausnitz and M. Langer, “Transdermal Drug Delivery,” Nat. Biotechnol., vol. 26, pp. 1261–1268, 2008.
8. Y. S. Murthy et al., “Barrier Function of Stratum Corneum in Transdermal Delivery,” Int. J. Pharm., vol. 537, pp. 1–11, 2018.
9. A. R. Prausnitz and M. Langer, “Transdermal Drug Delivery,” Nat. Biotechnol., vol. 26, pp. 1261–1268, 2008.
10. J. L. Berman and M. M. Berner, “Anatomy and Physiology of Skin Relevant to Drug Delivery,” J. Clin. Pharmacol., vol. 58, no. 4, pp. 345–356, 2019.
11. P. K. Sharma, “Enhancement Techniques in Transdermal Drug Delivery,” Pharm. Technol., vol. 44, no. 6, pp. 48–55, 2020.
12. M. S. Hadgraft, “Factors Affecting Percutaneous Absorption,” Clin. Pharmacokinet., vol. 41, no. 10, pp. 721–736, 2002.
13. R. Cevc, Liposomes and Skin: From Drug Delivery to Cosmetics, 2nd ed., New York: Marcel Dekker, 2004.
14. A. R. Prausnitz and M. Langer, “Transdermal Drug Delivery,” Nat. Biotechnol., vol. 26, pp. 1261–1268, 2008.
15. P. K. Sharma, “Chemical Enhancement Techniques in Transdermal Drug Delivery,” Pharm. Technol., vol. 44, no. 6, pp. 48–55, 2020.
16. V. D. Patil and S. B. Gosavi, “Supersaturation and Other Strategies in Transdermal Systems,” Asian J. Pharm. Res. Dev., 2025.
17. Y. S. Murthy et al., “Iontophoresis and Electroporation for Transdermal Drug Delivery,” Int. J. Pharm., vol. 537, pp. 1–11, 2018.
18. M. S. Hadgraft, “Physical Enhancement Techniques in Transdermal Delivery,” Clin. Pharmacokinet., vol. 41, no. 10, pp. 721–736, 2002.
19. R. Cevc, Microneedle and Skin Permeation Techniques, 2nd ed., New York: Marcel Dekker, 2004.
20. J. L. Berman and M. M. Berner, “Microneedle-Based Drug Delivery Systems,” J. Clin. Pharmacol., vol. 58, no. 4, pp. 345–356, 2019.
21. A. K. Jain and S. Jain, “Vesicular Systems for Transdermal Drug Delivery: Liposomes and Transfersomes,” Drug Dev. Ind. Pharm., vol. 44, no. 12, pp. 1873–1885, 2018.
22. P. Gupta et al., “Ethosomes and Niosomes for Enhanced Skin Delivery,” Int. J. Nanomedicine, vol. 12, pp. 637–655, 2017.
23. S. R. Singh and R. Kumar, “Nanoparticles and Nanoemulsions in Transdermal Delivery,” J. Control. Release, vol. 267, pp. 26–40, 2017.
24. P. K. Sharma, “Quality Control and Regulatory Considerations in Transdermal Systems,” Pharm. Technol., vol. 44, no. 6, pp. 48–55, 2020.
25. M. S. Hadgraft, “Skin Irritation and Sensitization in Transdermal Delivery,” Clin. Pharmacokinet., vol. 41, no. 10, pp. 721–736, 2002.
26. U.S. Food and Drug Administration (FDA), “Guidance for Industry: Nonsterile Transdermal and Topical Drug Products,” 2018.
27. J. L. Berman and M. M. Berner, “Anatomy and Physiology of Skin Relevant to Drug Delivery,” J. Clin. Pharmacol., vol. 58, no. 4, pp. 345–356, 2019.
28. R. Cevc, Microneedle and Skin Permeation Techniques, 2nd ed., New York: Marcel Dekker, 2004.
29. P. K. Sharma, “Enhancement Techniques in Transdermal Drug Delivery,” Pharm. Technol., vol. 44, no. 6, pp. 48–55, 2020.
30. A. R. Prausnitz and M. Langer, “Transdermal Drug Delivery,” Nat. Biotechnol., vol. 26, pp. 1261–1268, 2008.
31. V. D. Patil and S. B. Gosavi, “Personalized Approaches in Transdermal Drug Delivery,” Asian J. Pharm. Res. Dev., 2025.
32. S. R. Singh and R. Kumar, “Nanotechnology in Transdermal Drug Delivery,” J. Control. Release, vol. 267, pp. 26–40, 2017.
33. P. K. Sharma, “AI-Driven Optimization in Drug Delivery Systems,” Pharm. Technol., vol. 44, no. 6, pp. 48–55, 2020.
34. J. L. Berman and M. M. Berner, “3D-Printed Transdermal Systems: Future Perspectives,” J. Clin. Pharmacol., vol. 58, no. 4, pp. 345–356, 2019.
35. A. R. Prausnitz and M. Langer, “Long-Acting and Responsive Transdermal Patches,” Nat. Biotechnol., vol. 26, pp. 1261–1268, 2008.